Elotuzumab - National Cancer Institute ll NUEVO CAPÍTULO MÉDICO 2016

Elotuzumab - National Cancer Institute



New Drug for Multiple Myeloma 

A new summary about the drug elotuzumab. It was recently approved by the FDA to be used with other drugs to treat multiple myeloma in patients who have already received other treatment.

Elotuzumab

• 
• 
• 
• 
• 
• 
• 

(EH-loh-TOO-zoo-mab)

This page contains brief information about elotuzumab and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Empliciti

FDA Approved

Yes

FDA Approval for Elotuzumab

Use in Cancer

Elotuzumab is approved to be used with lenalidomide and dexamethasone to treat:

• Multiple myeloma in patients who have already received one to three other types of treatment.

More About Elotuzumab

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Targeted Cancer Therapies - Information about the use of this drug to treat cancer.

Clinical Trials Accepting Patients

Find Clinical Trials for Elotuzumab - Check for trials from NCI's list of cancer clinical trials now accepting patients.

Important: The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.

Elotuzumab - National Cancer Institute